


ONLINE SUPPLEMENT

<b>Lung diseases</b>	<b>ICD-10 codes</b>
Community-acquired pneumonia	J10, J11, J12, J13, J14, J15, J16, J17, and J18
Pneumocystis pneumonia	B206 and B59
Lung tuberculosis	A15, A16 and A19
Legionella pneumonia	A481
Aspergillosis pneumonia	B44.0 and B44.1
Pleural empyema	J86
Lung abscess	J85
Cytomegalovirus pneumonia	B250
Pneumothorax	J93
Chronic respiratory failure	J961
Lung cancer	C34 and C45
Pulmonary arterial hypertension (PAH)	I270
Sleep apnea	G473
Chronic obstructive pulmonary disease (COPD)	J40, J41, J42 and J44
Emphysema	J43 and J982
Asthma	J45 and J46
Pulmonary sarcoidosis	D86
Lung fibrosis	J841
Drug-induced pneumonia	J702 and J703
Pulmonary embolism	I26

Online supplement 1: Lung disease and respective ICD-10 codes identified in main or related diagnosis



Online supplement 2: Survival curve over time of 2010 prevalent hospitalized PLHIV with lung disease

Hazard ratios in PLHIV				
Gender	Female		Male	
HIV infection	Without AIDS	With AIDS	Without AIDS	With AIDS
At least one lung disease	1.5 (1.4-1.7)	3.8 (3.4-4.2)	1.3 (1.2-1.4)	2.8 (2.6-3.0)
At least one infectious lung disease	3.1 (2.7-3.6)	10.5 (9.4-11.8)	2.0 (1.8-2.2)	5.8 (5.3-6.2)
At least one non-infectious lung disease	1.2 (1.1-1.4)	2.0 (1.8-2.3)		1.8 (1.6-1.9)
COPD	1.4 (1.2-1.8)	2.0 (1.6-2.5)		1.3 (1.1-1.5)
Emphysema	2.3 (1.5-3.5)	3.1 (2.0-4.8)	2.1 (1.7-2.6)	2.5 (2.1-3.1)
Chronic respiratory failure	1.8 (1.4-2.4)	2.5 (1.8-3.4)		1.6 (1.4-2.0)
Lung fibrosis		3.4 (1.6-7.2)		3.5 (2.3-5.8)
PAH*	3.8 (2.6-5.8)	3.1 (1.8-5.4)	2.0 (1.4-2.8)	2.1 (1.4-3.1)
Lung cancer		2.0 (1.3-3.2)		1.7 (1.4-2.1)
Sleep apnea**		0.6 (0.3-0.9)	0.5 (0.4-0.6)	0.3 (0.2-0.4)

\* after adjusting for COPD and left heart dysfunction

\*\* after adjusting for obesity

Online supplement 3: Incident analysis over time for 2010 prevalent hospitalized HIV-AIDS to identify the effect of PLHIV with AIDS on lung disease, according to gender (after adjusting for age, and HBV or HBC infection) (Only statistically significant HRs are reported)

Hazard ratio in PLHIV with AIDS				
Age (in years)	18-29	30-49	50-69	over 70
At least one lung disease	9.1 (6.1-13.6)	7.2 (6.2-8.4)	5.2 (4.2-6.5)	5.7 (3.6-9.1)
At least one infectious lung disease	25.3 (16.1-40.0)	17.8 (14.9-21.2)	12.3 (9.6-15.9)	8.5 (4.7-15.3)
At least one non-infectious lung disease	2.7 (1.3-5.7)	2.6 (2.0-3.3)	2.0 (1.4-2.7)	2.4 (1.0-5.6)

Online supplement 4: Incident analysis over time for 2010 incident hospitalized HIV-AIDS to identify the effect of PLHIV with AIDS on lung disease, according to age group (after adjusting for gender, and HBV or HBC infection) (Only statistically significant HRs are reported)

Hazard ratio in smoker PLHIV without AIDS				
Age (in years)	18-29	30-49	50-69	over 70
At least one lung disease		1.2 (1.1-1.4)		
At least one infectious lung disease	4.0 (1.5-11.1)	1.8 (1.5-2.3)	1.3 (1.0-1.6)	
At least one non-infectious lung disease		1.5 (1.2-1.8)		
COPD				
Emphysema		1.6 (1.1-2.5)	1.5 (1.1-2.3)	
Chronic respiratory failure		1.6 (1.1-2.4)		
Lung fibrosis				
PAH				
Lung cancer				
Sleep apnea			0.4 (0.2-0.8)	

Online supplement 5: Incident analysis over time on smokers to identify the effect of PLHIV without AIDS on lung diseases, according to age group (after adjusting for gender, and HBV or HBC infection) (Only statistically significant HRs are reported)

Hazard ratio in smoker PLHIV with AIDS				
Age (in years)	18-29	30-49	50-69	over 70
At least one lung disease		1.7 (1.5-2.0)		
At least one infectious lung disease	3.7 (1.2-11.5)	3.8 (3.2-4.5)	2.4 (1.9-3.0)	
At least one non-infectious lung disease		1.5 (1.2-1.8)		
COPD				
Emphysema		2.0 (1.4-3.0)		
Chronic respiratory failure		2.1 (1.5-3.1)		
Lung fibrosis		4.9 (2.0-12.4)		
PAH		4.2 (2.3-7.5)		
Lung cancer		2.2 (1.4-3.4)		
Sleep apnea		0.2 (0.1-0.6)	0.3 (0.1-0.8)	

Online supplement 6: Incident analysis over time on smokers to identify the effect of PLHIV with AIDS on lung diseases, according to the age group (after adjusting for gender, and HBV or HBC infection) (Only statistically significant HRs are reported)